Company profile
Neurocrine Biosciences, Inc.
NASDAQ: NBIX · Healthcare · Biotechnology
#89 of 1,422 Healthcare companies by revenue68th-percentile growth
EA Score
88AFH 87DQ 93GM 76SS 93
v0.1 · 65/100 weight · provisional
↑ market scale, operating margin · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$3.1B
Rev growth YoY (TTM)
+28.6%
Net income (FY)
$478.6M
Employees
2,000
as of 2026-08-05
Market cap
$16.7B
as of 2026-08-05
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$2.9B$2.9B2025
Net income$478.6M$478.6M2025
Operating income$619.1M$619.1M2025
Total assets$4.6B$4.6B2025
Liabilities$1.4B$1.4B2025
Equity$3.3B$3.3B2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product99%
Collaboration Revenue1%
By geography
Not disclosed.
The read
What is Neurocrine Biosciences, Inc.’s revenue?
Neurocrine Biosciences, Inc. booked $2.9B in FY2025 revenue, growing 21% year over year — faster than most Healthcare companies we track, at a 16.7% net margin.
Peers · Healthcare
West Pharmaceutical Services, Inc.86AAmneal Pharmaceuticals, Inc.75B+Globus Medical, Inc.86ARevvity, Inc.79B+ModivCare Inc.——Accendra Health, Inc.62CNeighbors
San Diego →Key facts
CEOKyle W. Gano
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Diego, CA
ExchangeNASDAQ: NBIX
Employees2,000
IPO date1996-05-23
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.